DOSE-DEPENDENT ADVERSE-EFFECTS OF ASPIRIN TREATMENT IN PATIENTS WITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASE - RESULTS OF A CONTROLLED CLINICAL-TRIAL

Citation
C. Ranke et al., DOSE-DEPENDENT ADVERSE-EFFECTS OF ASPIRIN TREATMENT IN PATIENTS WITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASE - RESULTS OF A CONTROLLED CLINICAL-TRIAL, Medizinische Klinik, 88(10), 1993, pp. 571-576
Citations number
NO
Categorie Soggetti
Medicine, General & Internal
Journal title
ISSN journal
07235003
Volume
88
Issue
10
Year of publication
1993
Pages
571 - 576
Database
ISI
SICI code
0723-5003(1993)88:10<571:DAOATI>2.0.ZU;2-A
Abstract
Background and methods: In 359 patients with peripheral arterial occlu sive disease who had undergone percutaneous transluminal angioplasty ( PTA), a randomized double-blind, controlled clinical study was done to investigate the tolerability of acetyl salicylic acid (ASA) given for reocclusion prophylaxis. A comparison was made between a conventional daily dose of 900 mg ASA and a dose of 50 mg ASA. Results: Within an observation period of one year following PTA, 35 patients (20%) in the 900 mg group, and 32 patients (17%) in the 50 mg group left the trial because of side effects (p = NS). Under the higher dose, however, sev ere gastrointestinal side effects (ulcer, haemorrhagic gastritis requi ring transfusion) were significantly more common (nine patients corres ponds to 5.1% vs two patients corresponds to 1.1%, respectively; p = 0 .03). Overall, 107 patients (30%) reported subjective side effects suc h as upper abdominal pain, a sensation of fullness or nausea during th e course of the trial. 62 of these patients were from the 900 mg group (35%) as compared with 45 patients (24%) in the 50 mg group (p = 0.02 ). Self-scoring of epigastric pain on the basis of a visual analogue s cale revealed a score of 1.3 (95% confidence interval 0.9 to 1.6) in t he 900 mg group and 0.8 (95% confidence interval 0.6 to 1.0) in the 50 mg group. The subjective pain intensity showed a uniform time course for all three types of symptom, with a maximum after three months. Con clusion: Our results confirm the superior tolerability of the lower do se, in particular in elderly patients. For long-term treatment, the sm allest possible effective dose should be chosen.